SCHEMBL1925383

SCHEMBL1925383

COc1ccccc1NC(=O)Nc1ccc(-c2c(CCC(=O)O)c[nH]c2C(N)=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ROCK2 O75116 1/20 0.49
LIMK1 P53667 1/20 0.49
MAPT P10636 5/20 0.48
NPC1 O15118 4/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
THRB P10828 1/20 0.45
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
LMNA P02545 3/20 0.45
KIT P10721 1/20 0.45
KDR P35968 1/20 0.45
TEK Q02763 1/20 0.45
ALDH1A1 P00352 3/20 0.44
ITGB1 P05556 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1925163 0.88 MEN1 (0.50) RAB9ASMN1; SMN2ROCK2MAPTCA12
SCHEMBL1924610 0.88 MAPT (0.52) RAB9ASMN1; SMN2MAPTCA12CA1
SCHEMBL1924361 0.88 KMT2A (0.46) RAB9AROCK2MAPTNPC1MEN1
SCHEMBL1925746 0.88 ITGB1 (0.52) RAB9ASMN1; SMN2MAPTNPC1MEN1
SCHEMBL1926602 0.86 KDM4E (0.46) RAB9ASMN1; SMN2ROCK2LIMK1MAPT
SCHEMBL1926895 0.86 MAPT (0.41) RAB9ASMN1; SMN2ROCK2LIMK1MAPT
SCHEMBL1925337 0.86 PKM (0.47) RAB9ASMN1; SMN2MAPTNPC1CA12
SCHEMBL1923987 0.85 TSHR (0.50) RAB9ASMN1; SMN2ROCK2LIMK1MAPT
SCHEMBL1924115 0.84 RAB9A (0.58) RAB9ASMN1; SMN2L3MBTL1ROCK2LIMK1
SCHEMBL1924459 0.83 KDM4E (0.46) RAB9AROCK2MAPTNPC1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856043-B1 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER AVENTIS PHARMA SA (FR) 2011-06-08 EP claimed